Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients

Journal of Clinical Psychopharmacology - Tập 36 Số 4 - Trang 355-371 - 2016
Saínza García1,2, Mónica Martínez‐Cengotitabengoa3,1,4, Saioa López-Zurbano1, Eric P. Zorrilla3,1,2, Purificación López–Mahía3,1,2, Eduard Vieta1, Ana González‐Pinto3,1,2
1From the *Department of Psychiatry, University Hospital of Araba (Santiago), Vitoria; †University of the Basque Country, Bizkaia; ‡Biomedical Research Centre in Mental Health Network (CIBERSAM), University Hospital of Araba, Vitoria; §National University of Distance Education (UNED), Madrid; and ∥Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
2University of the Basque Country, Bizkaia
3Department of Psychiatry, University Hospital of Araba (Santiago), Vitoria
4National University of Distance Education (UNED), Madrid

Tóm tắt

Abstract Antipsychotics are the drugs prescribed to treat psychotic disorders; however, patients often fail to adhere to their treatment, and this has a severe negative effect on prognosis in these kinds of illnesses. Among the wide range of risk factors for treatment nonadherence, this systematic review covers those that are most important from the point of view of clinicians and patients and proposes guidelines for addressing them. Analyzing 38 studies conducted in a total of 51,796 patients, including patients with schizophrenia spectrum disorders and bipolar disorder, we found that younger age, substance abuse, poor insight, cognitive impairments, low level of education, minority ethnicity, poor therapeutic alliance, experience of barriers to care, high intensity of delusional symptoms and suspiciousness, and low socioeconomic status are the main risk factors for medication nonadherence in both types of disorder. In the future, prospective studies should be conducted on the use of personalized patient-tailored treatments, taking into account risk factors that may affect each individual, to assess the ability of such approaches to improve adherence and hence prognosis in these patients.

Từ khóa


Tài liệu tham khảo

2009, Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response, J Clin Psychiatry, 70, 990, 10.4088/JCP.08m04221

2003, How often do patients with psychosis fail to adhere to treatment programmes? A systematic review, Psychol Med, 33, 1149, 10.1017/S0033291703008328

1976, Improvement of medication compliance in uncontrolled hypertension, Lancet, 1, 1265

1999, Compliance in psychoses, Acta Psychiatr Scand, 100, 167, 10.1111/j.1600-0447.1999.tb10842.x

2003, Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia, Schizophr Res, 63, 49, 10.1016/S0920-9964(02)00314-6

2000, Clinical factors associated with treatment noncompliance in euthymic bipolar patients, J Clin Psychiatry, 61, 549, 10.4088/JCP.v61n0802

2010, Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia, Psychiatry Res, 176, 109, 10.1016/j.psychres.2009.05.004

1999, Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients, Psychiatry Res, 89, 247, 10.1016/S0165-1781(99)00108-0

2002, Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization, Am J Psychiatry, 159, 1927, 10.1176/appi.ajp.159.11.1927

2005, Improving treatment adherence in bipolar disorder through psychoeducation, J Clin Psychiatry, 66, 24

1996, Psychological predictors of insight and compliance in psychotic patients, Br J Psychiatry, 169, 444, 10.1192/bjp.169.4.444

1997, Determinants of medication compliance in schizophrenia: empirical and clinical findings, Schizophr Bull, 23, 637, 10.1093/schbul/23.4.637

2013, Predictors of medication adherence in patients with schizophrenia and bipolar disorder, Acta Psychiatr Scand, 127, 23, 10.1111/j.1600-0447.2012.01911.x

1998, Compliance with medication regimens for mental and physical disorders, Psychiatr Serv, 49, 196, 10.1176/ps.49.2.196

2002, Treatment non-adherence in affective disorders, Acta Psychiatr Scand, 105, 164, 10.1034/j.1600-0447.2002.1r084.x

2002, Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature, J Clin Psychiatry, 63, 892, 10.4088/JCP.v63n1007

2005, Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals, Arch Gen Psychiatry, 62, 717, 10.1001/archpsyc.62.7.717

2009, Treatment nonadherence and neurocognitive impairment in bipolar disorder, J Clin Psychiatry, 70, 1017, 10.4088/JCP.08m04408

2009, The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness, J Clin Psychiatry, 70, 1, 10.4088/JCP.7090su1cj

2013, Examining levels of antipsychotic adherence to better understand nonadherence, J Clin Psychopharmacol, 33, 261, 10.1097/JCP.0b013e31828568bc

1998, Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle, Psychol Med, 28, 351, 10.1017/S0033291797006399

2003, Clinical correlates of early medication adherence: West London first episode schizophrenia study, Acta Psychiatr Scand, 108, 439, 10.1046/j.0001-690X.2003.00193.x

2000, Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects, Acta Psychiatr Scand, 102, 203, 10.1034/j.1600-0447.2000.102003203.x

2010, Assessment of medication adherence in a cohort of patients with bipolar disorder, Pharmacopsychiatry, 43, 263, 10.1055/s-0030-1263169

2006, Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment, Bipolar Disord, 8, 618, 10.1111/j.1399-5618.2006.00368.x

2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100

2000, Predicting medication adherence in severe mental disorders, Acta Psychiatr Scand, 101, 119, 10.1034/j.1600-0447.2000.90061.x

2008, Factors associated with treatment nonadherence among US bipolar disorder patients, Hum Psychopharmacol, 23, 95, 10.1002/hup.908

2007, Depot antipsychotic medications in bipolar disorder: a review of the literature, Acta Psychiatr Scand Suppl, 3

2002, Medication adherence of individuals with a first episode of psychosis, Acta Psychiatr Scand, 106, 286, 10.1034/j.1600-0447.2002.02437.x

1995, Medication self-management: a preliminary report on an intervention to improve medication compliance, J Ment Health, 4, 511, 10.1080/09638239550037343

2015, Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies, Eur Neuropsychopharmacol, 25, 1158, 10.1016/j.euroneuro.2015.04.003

1994, Depot antipsychotic drugs. Place in therapy, Drugs, 47, 741, 10.2165/00003495-199447050-00004

2012, Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial, BMC Med Res Methodol, 12, 142, 10.1186/1471-2288-12-142

2005, Factors associated with medication adherence in African American and white patients with bipolar disorder, J Clin Psychiatry, 66, 646, 10.4088/JCP.v66n0517

2007, Factors that affect adherence to bipolar disorder treatments: a stated-preference approach, Med Care, 45, 545, 10.1097/MLR.0b013e318040ad90

2008, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial, Lancet, 371, 1085, 10.1016/S0140-6736(08)60486-9

2007, Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia, J Clin Psychiatry, 68, 75, 10.4088/JCP.v68n0110

2007, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials, J Clin Psychiatry, 68, e04

2006, Effect of subjective reasoning and neurocognition on medication adherence for persons with schizophrenia, Psychiatr Serv, 57, 1203, 10.1176/ps.2006.57.8.1203

2003, Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program, Psychiatr Serv, 54, 719, 10.1176/appi.ps.54.5.719

2009, A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia, Schizophr Res, 113, 138, 10.1016/j.schres.2009.04.018

2008, Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain, Appl Health Econ Health Policy, 6, 41, 10.2165/00148365-200806010-00004

2008, A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral, J Clin Psychiatry, 69, 1548, 10.4088/JCP.v69n1004

2002, Predictors of noncompliance in patients with schizophrenia, J Clin Psychiatry, 63, 1121, 10.4088/JCP.v63n1206

2008, Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study, J Clin Psychiatry, 69, 106, 10.4088/JCP.v69n0114

2010, Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study, J Clin Psychiatry, 71, 296, 10.4088/JCP.09m05514yel

2006, Treatment adherence with antipsychotic medications in bipolar disorder, Bipolar Disord, 8, 232, 10.1111/j.1399-5618.2006.00314.x

2009, Medication treatment perceptions, concerns and expectations among depressed individuals with type I bipolar disorder, J Affect Disord, 115, 360, 10.1016/j.jad.2008.10.002

2015, A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders, Psychiatry Res, 225, 14, 10.1016/j.psychres.2014.11.002

2010, Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis, Pharmacopsychiatry, 43, 281, 10.1055/s-0030-1263172

2004, Obesity as a risk factor for antipsychotic noncompliance, Schizophr Res, 66, 51, 10.1016/S0920-9964(02)00498-X

2008, Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder, J Affect Disord, 107, 53, 10.1016/j.jad.2007.07.026

2005, Defining and measuring clinical effectiveness in the treatment of schizophrenia, Psychiatr Serv, 56, 273, 10.1176/appi.ps.56.3.273

2005, Is adolescent-onset first-episode psychosis different from adult onset?, J Am Acad Child Adolesc Psychiatry, 44, 782, 10.1097/01.chi.0000164591.55942.ea

2010, The personal meaning of romantic relationships for young people with psychosis, Clin Child Psychol Psychiatry, 15, 151, 10.1177/1359104509341447

2011, Early intervention for psychosis, Cochrane Database Syst Rev, CD004718

2008, Early intervention in psychosis: concepts, evidence and future directions, World Psychiatry, 7, 148, 10.1002/j.2051-5545.2008.tb00182.x

1998, Early intervention in psychosis. The critical period hypothesis, Br J Psychiatry Suppl, 172, 53, 10.1192/S0007125000297663

2014, Drug attitude in adolescents: a key factor for a comprehensive assessment, J Clin Psychopharmacol, 34, 99, 10.1097/JCP.0000000000000035

2007, Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis, Schizophr Res, 96, 232, 10.1016/j.schres.2007.07.022

2012, Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis, J Clin Psychopharmacol, 32, 465, 10.1097/JCP.0b013e31825d3763

2013, Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder, J Clin Psychopharmacol, 33, 343, 10.1097/JCP.0b013e3182900c6f

2008, Treatment of first-episode and prodromal signs, Psychiatry, 7, 467, 10.1016/j.mppsy.2008.10.001

2011, Schizophrenia, an illness with bad outcome: myth or reality?, Can J Psychiatry, 56, 92, 10.1177/070674371105600204

2015, Offering financial incentives to increase adherence to antipsychotic medication: the clinician experience, J Clin Psychopharmacol, 35, 120, 10.1097/JCP.0000000000000276

2013, Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study, BMC Psychiatry, 13, 326, 10.1186/1471-244X-13-326

2006, Self-reported medication treatment adherence among veterans with bipolar disorder, Psychiatr Serv, 57, 56, 10.1176/appi.ps.57.1.56

2010, Clozapine versus other atypical antipsychotics for schizophrenia, Cochrane Database Syst Rev, CD006633

2009, Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL [in French], Encephale, 35, 25

2006, Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1), Arch Gen Psychiatry, 63, 1079, 10.1001/archpsyc.63.10.1079

2003, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine, Neuropsychopharmacology, 28, 995, 10.1038/sj.npp.1300157

2012, Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons, Schizophr Bull, 38, 167, 10.1093/schbul/sbq042

2015, Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance, Curr Opin Psychiatry, 28, 216, 10.1097/YCO.0000000000000160

1999, Polymorphic cytochromes P450 and drugs used in psychiatry, Cell Mol Neurobiol, 19, 325, 10.1023/A:1006945715127

1996, Influence of pharmacogenetics on drug disposition and response, Clin Exp Pharmacol Physiol, 23, 983, 10.1111/j.1440-1681.1996.tb01154.x

2014, Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics, OMICS, 18, 402, 10.1089/omi.2014.0018

2014, A call for pharmacogenovigilance and rapid falsification in the age of big data: why not first road test your biomarker?, OMICS, 18, 663, 10.1089/omi.2014.0132

2003, Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project, J Clin Oncol, 21, 3859, 10.1200/JCO.2003.04.537

2011, Pharmacogenomic research in South Africa: lessons learned and future opportunities in the Rainbow Nation, Curr Pharmacogenomics Person Med, 9, 191, 10.2174/187569211796957575

2013, Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat, Transl Psychiatry, 3, e309, 10.1038/tp.2013.83

2013, Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder, J Clin Psychopharmacol, 33, 759, 10.1097/JCP.0b013e3182a1cd2e

2011, Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec [in French], Can J Psychiatry, 56, 367, 10.1177/070674371105600608

2008, Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives, Psychol Med, 38, 771, 10.1017/S0033291707001675

2013, Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study, Am J Psychiatry, 170, 852, 10.1176/appi.ajp.2012.12070971

2008, The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia, Schizophr Bull, 34, 483

2013, Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial, J Clin Psychopharmacol, 33, 258, 10.1097/JCP.0b013e3182856886

2015, Personalised medicine applied to mental health: precision psychiatry [in Spanish], Rev Psiquiatr Salud Ment, 8, 117

2016, Bipolar disorder, Lancet, 387, 1561, 10.1016/S0140-6736(15)00241-X

Thông tin
Thông tin xuất bản

Journal of Clinical Psychopharmacology

Tập 36 Số 4

355-371

Thông tin tác giả